REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

02/03/2021 15:50

RNS Number : 9116Q
  
GlaxoSmithKline PLC
  
02 March 2021
  
 

GlaxoSmithKline plc (the 'Company')
 
Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American Depository Shares
This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares ('ADSs') made in 2018 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares and ADSs to meet tax liabilities. In accordance with the shareholder approved 2017 Remuneration Policy and the DABP rules, the awards were comprised of a mandatory bonus deferral only. The three-year restricted period for the Deferred Bonus Awards commenced on 1 March 2018 and ended on 1 March 2021.  Dividends accrued on the Awards during the restricted period.
The awards were granted in 2018 as restricted awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.
The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on 1 March 2021 were £12.0060 and $33.73.
 
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£0.00


68,716


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£12.1070


32,346


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£0.00


14,551


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£12.1113


6,857


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics and Compliance




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£0.00


7,630


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics and Compliance




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£12.1132


3,599


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
 
ISIN: US37733W1053




b)


Nature of the transaction


The vesting of an award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$0.00


7,346


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
                       




e)


Date of the transaction


2021-03-01
 




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
 
ISIN: US37733W1053




b)


Nature of the transaction


The sale of ADSs' to meet tax liabilities on the vesting of an award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$33.7970


3,756


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
                       




e)


Date of the transaction


2021-03-01
 




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£0.00


13,820


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£12.0992


6,501


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£0.00


14,126


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£12.1093


6,656


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms K Terrell




b)


Position/status


Chief Digital & Technology Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
 
ISIN: US37733W1053




b)


Nature of the transaction


The vesting of an award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$0.00


2,480


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
                       




e)


Date of the transaction


2021-03-01
 




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms K Terrell




b)


Position/status


Chief Digital & Technology Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
 
ISIN: US37733W1053




b)


Nature of the transaction


The sale of ADSs' to meet tax liabilities on the vesting of an award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$33.7970


976


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
                       




e)


Date of the transaction


2021-03-01
 




f)


Place of the transaction
 


N/A




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£0.00


9,555


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2018 under the Company's 2017 Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£12.1030


4,507


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-03-01




f)


Place of the transaction
 


N/A




 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHELLFBFXLZBBQ